Loading asset research
Inhibrx Biosciences Inc. Common Stock
INBXNasdaq · USD · StocksQuote as of · Exchange session not verified$108.93
-2.23%
Today
INBX
Loading 1D prices…
Market cap
$1.6B
Volume
211K
52w high
$155.2952w low
$26.19Company profile
Inhibrx Biosciences Inc. Common Stock
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
La Jolla, CA, United States
Employees
109
Fiscal year end
1231
CIK
2007919
Session & valuation
Open$113.00
Previous close$111.42
Day high$115.11
Day low$108.93
30-day avg. volume320.5K
Outstanding shares14.7M
Diluted EPS-$9.04
Latest annual period
P/E (trailing)-12.05
P/E (forward)-12.47
Price / book-30.34
Beta3.67
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TSHATaysha Gene Therapies Inc. Common Stock | $1.6B | $9.8M | -1115.27% | -$0.34 | -2.81% | Buy |
| NVAXNovavax Inc. Common Stock | $1.6B | $1.1B | +39.19% | $2.58 | +1.34% | Hold |
| IMCRImmunocore Holdings plc American Depositary Shares | $1.7B | $400M | -8.88% | -$0.71 | -3.04% | Buy |
| RXRXRecursion Pharmaceuticals Inc. Class A Common Stock | $1.7B | $74.7M | -863.35% | -$1.44 | +1.11% | Hold |
| VIRVir Biotechnology Inc. Common Stock | $1.8B | $68.6M | -638.87% | -$3.16 | +0.33% | Buy |